Viridian Therapeutics, Inc.\DE (VRDN) Amortization of Deferred Charges (2021 - 2025)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Amortization of Deferred Charges of $103000.0 for Q2 2025, down 16.26% year-over-year from $123000.0 in Q2 2024, and little changed quarter-over-quarter from $103000.0 in Q1 2025.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Amortization of Deferred Charges (2021 - 2025) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $103000.0 for Q2 2025.
- In Q2 2025, Amortization of Deferred Charges fell 16.26% year-over-year to $103000.0; the TTM figure through Jun 2025 stood at $337000.0 (down 26.1% YoY), while the FY2024 annual figure was $377000.0, up 18.93% from the prior year.
- Amortization of Deferred Charges for Q2 2025 stood at $103000.0, roughly flat from $103000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $128000.0 in Q4 2022, with the low at $49000.0 in Q3 2022.
- The 5-year median for Amortization of Deferred Charges is $87000.0 (2021), against an average of $86785.7.
- Peak annual rise in Amortization of Deferred Charges reached 132.08% in 2024, while the deepest fall reached 52.03% in 2024.
- Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges stood at $87000.0 in 2021, then jumped by 47.13% to $128000.0 in 2022, then decreased by 3.91% to $123000.0 in 2023, then slumped by 52.03% to $59000.0 in 2024, then soared by 74.58% to $103000.0 in 2025.
- Business Quant data shows VRDN's Amortization of Deferred Charges at $103000.0 in Q2 2025, $103000.0 in Q1 2025, and $59000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 103,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Sep 30, 2024 | 72,000.00 |
| Jun 30, 2024 | 123,000.00 |
| Mar 31, 2024 | 123,000.00 |
| Dec 31, 2023 | 123,000.00 |
| Sep 30, 2023 | 87,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | 53,000.00 |
| Dec 31, 2022 | 128,000.00 |
| Sep 30, 2022 | 49,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Dec 31, 2021 | 87,000.00 |